Literature DB >> 7866703

The 5' noncoding region and virulence of poliovirus vaccine strains.

A J Macadam1, D M Stone, J W Almond, P D Minor.   

Abstract

All three live, attenuated vaccine strains of poliovirus contain important attenuation determinants in a short conserved sequence in the 5' noncoding region. Evidence suggests these act by weakening a secondary-structural element critical for the unusual mechanism of translational initiation of picornaviruses, in which ribosomes bind directly to a site far downstream of the 5' end. Understanding the molecular basis of attenuation may allow novel vaccine strains to be designed.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7866703     DOI： 10.1016/0966-842x(94)90803-6

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


  17 in total

1.  Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion.

Authors:  J Martín; G Dunn; R Hull; V Patel; P D Minor
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.

Authors:  S Butrapet; C Y Huang; D J Pierro; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 3.  RNA-protein interactions in regulation of picornavirus RNA translation.

Authors:  G J Belsham; N Sonenberg
Journal:  Microbiol Rev       Date:  1996-09

4.  Direct detection of Sabin poliovirus vaccine strains in stool specimens of first-dose vaccinees by a sensitive reverse transcription-PCR method.

Authors:  D A Buonagurio; J W Coleman; S A Patibandla; B S Prabhakar; J M Tatem
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

Review 5.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

6.  Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization.

Authors:  Jennifer L Konopka-Anstadt; Ray Campagnoli; Annelet Vincent; Jing Shaw; Ling Wei; Nhien T Wynn; Shane E Smithee; Erika Bujaki; Ming Te Yeh; Majid Laassri; Tatiana Zagorodnyaya; Amy J Weiner; Konstantin Chumakov; Raul Andino; Andrew Macadam; Olen Kew; Cara C Burns
Journal:  NPJ Vaccines       Date:  2020-03-20       Impact factor: 7.344

7.  Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication.

Authors:  Andrew J Macadam; Geraldine Ferguson; David M Stone; Janet Meredith; Sarah Knowlson; Ghazi Auda; Jeffrey W Almond; Philip D Minor
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

8.  Genomic analysis of vaccine-derived poliovirus strains in stool specimens by combination of full-length PCR and oligonucleotide microarray hybridization.

Authors:  Majid Laassri; Eugenia Dragunsky; Joan Enterline; Tatiana Eremeeva; Olga Ivanova; Kathleen Lottenbach; Robert Belshe; Konstantin Chumakov
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

9.  A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3.

Authors:  K U Knowlton; E S Jeon; N Berkley; R Wessely; S Huber
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 10.  Role of RNA structure motifs in IRES-dependent translation initiation of the coxsackievirus B3: new insights for developing live-attenuated strains for vaccines and gene therapy.

Authors:  Amira Souii; Manel Ben M'hadheb-Gharbi; Jawhar Gharbi
Journal:  Mol Biotechnol       Date:  2013-10       Impact factor: 2.695
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.